UroGen Pharma Ltd. Increase (Decrease) in Accounts Payable and Accrued Liabilities
UroGen Pharma Ltd. (URGN) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $12.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-05
- UroGen Pharma Ltd. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $4.60M, a 618.59% increase year-over-year.
- UroGen Pharma Ltd. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $7.63M, a 163.89% increase year-over-year.
- UroGen Pharma Ltd. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $1.54M, a 80.07% decline year-over-year.
- UroGen Pharma Ltd. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$4.79M.
- UroGen Pharma Ltd. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $286.00K, a 97.37% decline from fiscal 2024.
- UroGen Pharma Ltd. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $10.89M, a 162.17% increase from fiscal 2023.
- UroGen Pharma Ltd. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $4.16M, a 1378.65% increase from fiscal 2022.
- UroGen Pharma Ltd. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $281.00K, a 85.94% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $12.23M 10-Q · filed 2026-08-05 | $13.77M derived: sum of 3 quarters · filed 2026-08-05 | $8.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $7.63M 10-Q · filed 2026-05-06 | $9.17M derived: sum of 2 quarters · filed 2026-05-06 | $4.38M derived: sum of 3 quarters · filed 2026-05-06 | $5.02M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$3.25M derived: sum of 2 quarters · filed 2026-03-02 | -$2.60M derived: sum of 3 quarters · filed 2026-08-05 | $286.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | -$4.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.15M derived: sum of 2 quarters · filed 2026-08-05 | -$1.26M 10-Q · filed 2025-11-06 | $6.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $640.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.53M 10-Q · filed 2026-08-05 | $11.28M derived: sum of 3 quarters · filed 2026-08-05 | $7.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.89M 10-Q · filed 2026-05-06 | $10.64M derived: sum of 2 quarters · filed 2026-05-06 | $6.57M derived: sum of 3 quarters · filed 2026-05-06 | $12.16M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $7.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $3.68M derived: sum of 2 quarters · filed 2026-03-02 | $9.27M derived: sum of 3 quarters · filed 2026-03-02 | $10.89M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$4.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.53M derived: sum of 2 quarters · filed 2025-11-06 | $3.15M 10-Q · filed 2025-11-06 | $5.60M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $7.22M 10-Q · filed 2025-08-07 | $9.67M derived: sum of 3 quarters · filed 2025-08-07 | $7.35M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.62M 10-Q · filed 2025-05-12 | $4.08M derived: sum of 2 quarters · filed 2025-05-12 | $1.75M derived: sum of 3 quarters · filed 2025-05-12 | $1.03M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $135.00K derived: sum of 2 quarters · filed 2025-03-10 | -$592.00K derived: sum of 3 quarters · filed 2025-03-10 | $4.16M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$2.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$3.05M derived: sum of 2 quarters · filed 2024-11-06 | $1.70M 10-Q · filed 2024-11-06 | $4.73M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$727.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $4.02M 10-Q · filed 2024-08-13 | $7.05M derived: sum of 3 quarters · filed 2024-08-13 | $7.75M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $4.75M 10-Q · filed 2024-05-13 | $7.77M derived: sum of 2 quarters · filed 2024-05-13 | $8.48M derived: sum of 3 quarters · filed 2024-05-13 | $7.20M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $3.73M derived: sum of 2 quarters · filed 2024-03-14 | $2.45M derived: sum of 3 quarters · filed 2024-03-14 | $281.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $708.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$577.00K derived: sum of 2 quarters · filed 2023-11-14 | -$2.75M 10-Q · filed 2023-11-14 | -$1.78M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$3.45M 10-Q · filed 2023-08-10 | -$2.49M derived: sum of 3 quarters · filed 2023-08-10 | -$1.77M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$2.17M 10-Q · filed 2023-05-11 | -$1.20M derived: sum of 2 quarters · filed 2023-05-11 | -$490.00K derived: sum of 3 quarters · filed 2023-05-11 | -$706.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $966.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $1.68M derived: sum of 2 quarters · filed 2023-03-24 | $1.46M derived: sum of 3 quarters · filed 2023-03-24 | $2.00M 10-K · filed 2023-03-24 |
| 2021-09-30 | $713.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $497.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.03M 10-Q · filed 2022-11-10 | $2.29M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$216.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $319.00K 10-Q · filed 2022-08-11 | $1.58M derived: sum of 3 quarters · filed 2022-08-11 | $1.12M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $535.00K 10-Q · filed 2022-05-10 | $1.80M derived: sum of 2 quarters · filed 2022-05-10 | $1.34M derived: sum of 3 quarters · filed 2022-05-10 | $1.79M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $801.00K derived: sum of 2 quarters · filed 2022-03-21 | $1.25M derived: sum of 3 quarters · filed 2022-03-21 | -$1.25M 10-K · filed 2022-03-21 |
| 2020-09-30 | -$460.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$8.00K derived: sum of 2 quarters · filed 2021-11-15 | -$2.51M 10-Q · filed 2021-11-15 | $612.00K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $452.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$2.05M 10-Q · filed 2021-08-04 | $1.07M derived: sum of 3 quarters · filed 2021-08-04 | $1.88M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | -$2.50M 10-Q · filed 2021-05-13 | $620.00K derived: sum of 2 quarters · filed 2021-05-13 | $1.43M derived: sum of 3 quarters · filed 2021-05-13 | $2.87M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $3.93M derived: sum of 2 quarters · filed 2021-03-18 | $5.37M derived: sum of 3 quarters · filed 2021-03-18 | $2.93M 10-K · filed 2021-03-18 |
| 2019-09-30 | $809.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $2.25M derived: sum of 2 quarters · filed 2020-11-09 | -$190.00K 10-Q · filed 2020-11-09 | $1.96M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$999.00K 10-Q · filed 2020-08-10 | $1.15M derived: sum of 3 quarters · filed 2020-08-10 | $1.78M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | -$2.44M 10-Q · filed 2020-05-07 | -$293.00K derived: sum of 2 quarters · filed 2020-05-07 | $343.00K derived: sum of 3 quarters · filed 2020-05-07 | $1.97M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $2.78M derived: sum of 2 quarters · filed 2020-03-02 | $4.41M derived: sum of 3 quarters · filed 2020-03-02 | $4.21M 10-K · filed 2020-03-02 |
| 2018-09-30 | $636.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $2.26M derived: sum of 2 quarters · filed 2019-11-12 | $2.06M 10-Q · filed 2019-11-12 | $2.89M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $1.42M 10-Q · filed 2019-08-09 | $2.25M derived: sum of 3 quarters · filed 2020-03-02 | $2.92M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$206.00K 10-Q · filed 2019-05-09 | $624.00K derived: sum of 2 quarters · filed 2020-03-02 | $1.30M derived: sum of 3 quarters · filed 2020-03-02 | $1.94M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $830.00K derived: 10-K 12 month − 6-K 9 month · filed 2020-03-02 | $1.50M derived: sum of 2 quarters · filed 2020-03-02 | $2.15M derived: sum of 3 quarters · filed 2020-03-02 | $2.53M 10-K · filed 2020-03-02 |
| 2017-09-30 | $673.00K derived: 6-K 9 month − 6-K 6 month · filed 2018-11-13 | $1.32M derived: sum of 2 quarters · filed 2018-11-13 | $1.70M 6-K · filed 2018-11-13 | |
| 2017-06-30 | $647.00K derived: 6-K 6 month − 6-K 3 month · filed 2018-08-14 | $1.03M 6-K · filed 2018-08-14 | ||
| 2017-03-31 | $384.00K 6-K · filed 2018-05-15 | |||
| 2016-12-31 | $481.00K 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $1.16M 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |